The journal article, 'autologous hematopoietic stem cell transplantation for liver transplant recipients with recurrent primary sclerosing cholangitis: a pilot study' describes a study whether autologous hematopoietic stem cell transplantation (ahsct) could be used to stop progression of recurrent primary sclerosing cholangitis (psc) and promote operational tolerance after liver transplantation.Five patients with clinical, biochemical, radiologic, and histologic evidence of recurrent psc underwent ahsct.Ahsc grafts were collected with a single leukapheresis procedure in all 5 patients."in this pilot study of 5 patients who underwent ahsct for recurrent psc following liver transplantation, 2 are alive and have been off immunosuppressive drugs without evidence of progression of psc or allograft rejection for >3 y, consistent with operational tolerance to self-antigens and alloantigens.However, the myeloablative conditioning regimen (ctx, busulfan, and antithymocyte globulin) had significant toxicity in all of the patients and led to death or the need for repeat liver transplantation in 3 of the 5 patients." three of the 5 patients required admission to an intensive care unit and these 3 patients required a short course of renal replacement therapy (hemodialysis).Patient 4 succumbed to multiorgan failure and sepsis on day 87 post-ahsct.This report is being filed for patient 4.Further patient information is not provided in the article.The leukapheresis sets are not available for return for evaluation.
|
Lot number and expiry are not available at this time.Article citation: chruscinski, a., et.Al.2022.Autologous hematopoietic stem cell transplantation for liver transplant recipients with recurrent primary sclerosing cholangitis: a pilot study.Transplantation.106:3, 562¿574.Doi: 10.1097/tp.0000000000003829 investigation is in process.A follow up report will be provided.
|